Pharma BD Deal Intelligence

Multiplex Bio / Standard BioTools Inc.

2026 · Asset Purchase · $10M · Pending

Standard BioTools Inc. announced on 2026-07-28 the sale of its mass cytometry business to Multiplex Bio, a company founded by Michael Johnson, Tom Villani and Charles Coffman, for up to $10 million comprising a seller's note and a potential milestone payment. Standard BioTools is also providing a working capital loan of up to $10 million. The divested business will continue to operate under the Standard BioTools name and the transaction is expected to close by the end of 2026. The divestiture is one of several steps advancing Standard BioTools' pending merger with Treeline Biosciences. NOTE: ingested at pending_review on single-source corroboration; a second independent source was not located this run.

Key facts

• Announced Jul 28, 2026
• Deal value $10M
• Deal type Asset Purchase

Related deals

• Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. (2026)
• Servier / Edgewise Therapeutics, Inc. (2026)
• AstraZeneca PLC / Dizal Pharmaceutical Co., Ltd (2026)
• Travere Therapeutics, Inc. / Everest Medicines Limited (2026)
• AbbVie Inc. / Apogee Therapeutics, Inc. (2026)
• Pfizer Inc. / Innovent Biologics, Inc. (2026)

← Browse all deals  ·  How we score deals

More: 2026 deals